Summary
This exploratory analysis of data from four clinical trials of pembrolizumab, a PD-1 checkpoint inhibitor, examined over 300 patient samples across 22 tumour types to evaluate the predictive value of genomic and immunological biomarkers. Two proposed signatures—tumour mutational burden and a T cell-inflamed microenvironment—were analysed both independently and in combination to assess their utility in predicting immunotherapy response. The findings suggest that TMB and GEP capture distinct biological features and may have complementary predictive value, though the abstract does not provide detailed effect sizes or overall accuracy metrics.
UK applicability
This research is directly applicable to UK oncology practice, where pembrolizumab and other PD-1 inhibitors are standard treatments for multiple cancer types. The identification of predictive biomarkers could inform patient selection and stratification within NHS cancer services, though implementation would require validation in UK patient populations and integration with routine diagnostic pathways.
Key measures
Tumour mutational burden (TMB); T cell-inflamed gene expression profile (GEP); patient response rates to pembrolizumab; correlation between TMB and GEP
Outcomes reported
The study evaluated tumour mutational burden (TMB) and T cell-inflamed gene expression profile (GEP) as predictive biomarkers for pembrolizumab response across 300+ patient samples spanning 22 tumour types. The analysis assessed the joint and independent predictive utility of these two biomarkers in identifying responders and non-responders to PD-1 checkpoint blockade immunotherapy.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.